Recurrent Implantation Failure: Why Did a Euploid Embryo Fail?

By Seungjoo Lee · Evidence guide · Updated October 5, 2026

A euploid embryo, a carefully planned IVF transfer—and another negative test. Why can an embryo with a normal PGT-A result still fail? This recurrent implantation failure guide separates what a failed euploid embryo transfer tells you from what it cannot prove, explains why failure counts need context, and brings together evidence on additional tests and the next transfer.

Start here: One unsuccessful transfer does not identify a cause. Before choosing another test, establish which outcome occurred, what has already been checked, and how a new result would change care.

In this guide: Euploid does not mean guaranteed · Failure counts · Additional tests · Your next consultation

Why can a euploid embryo transfer fail?

A euploid PGT-A result describes the chromosome findings in sampled embryo cells. It is not a certificate that every step between transfer and birth will succeed. Embryo development, the uterine environment and the transfer process still matter. A negative result alone cannot tell you which factor mattered in that cycle—or establish that your immune system rejected the embryo.

There is also an essential distinction between no positive pregnancy test, a biochemical pregnancy and a later miscarriage. A pregnancy that began and then ended needs a different discussion from a transfer with no detected implantation. Bring the actual hCG results and ultrasound reports rather than grouping every outcome under “failed IVF.”

How many failed transfers count as recurrent implantation failure?

There is no single universally accepted count. ASRM’s 2026 framework uses failure after enough good-quality blastocysts to produce an estimated 95% cumulative chance of a positive pregnancy test; the cited literature suggests roughly three to six euploid transfers, with age-dependent interpretation for untested embryos. This is a probability-based framework, not a rule that every patient must undergo six transfers before review. Read the ASRM opinion.

ESHRE’s 2023 recommendations instead proposed a cumulative predicted implantation chance above 60% as a threshold for discussing further investigation after unsuccessful transfers. The difference matters: these professional frameworks are not interchangeable definitions of a fixed disease. Both require the individual clinical context. Read ESHRE’s recommendations.

Explore our article on the changing definition of recurrent implantation failure.

What does “92% by the third transfer” actually mean?

A retrospective NYU study followed 5,811 patients through 7,763 single euploid embryo transfers. Estimated cumulative live birth probability rose from 63.1% after one transfer to 92.0% after three. That is an estimate across successive attempts, not a 92% success rate for the third transfer itself.

The study included patients who obtained euploid embryos and could continue treatment. Its results cannot promise the same outcome to someone with only one embryo available, and a single-center observational cohort cannot establish the best treatment for everyone. It supports a conversation about remaining opportunities without requiring anyone to continue treatment beyond their own limits. Durbin and colleagues, Fertility and Sterility, 2026.

Read the full explanation of sequential euploid transfers and cumulative live birth.

Which additional tests deserve a discussion?

Start with a review of previous records, uterine and tubal assessment where indicated, and the details of embryo development, transfer and medication timing. ASRM does not support routine use of several commonly marketed add-ons for RIF; endometrial scratching is not recommended, and routine ERA and immunotherapy lack sufficient supporting evidence. ASRM, 2026.

A suspected structural problem: ESHRE says hysteroscopy can be considered, particularly when ultrasound suggests a uterine abnormality. This is different from assuming everyone needs the same procedure.
Chronic endometritis: Investigation and treatment can be considered in selected RIF cases, but diagnostic thresholds and treatment evidence are inconsistent. An antibiotic course is not a universal implantation remedy.
A commercial receptivity test: ESHRE finds insufficient evidence for routine use to diagnose the cause of RIF. Ask whether changing care based on the result improves live birth—not simply whether the test can produce an “abnormal” label.

Source: ESHRE good practice recommendations (2023). Our detailed review of RIF tests and add-on treatments explains the broader debate.

A useful plan for the next consultation

Write a one-page timeline: transfer date, embryo stage and testing status, preparation protocol, progesterone instructions, hCG results and any subsequent scan. Add what you found difficult—visits, injections, cost or recovery time. These practical details belong in the decision, alongside laboratory results.

Which of my outcomes were implantation failures, and which were pregnancy losses?
What specific finding makes further investigation appropriate now?
For each proposed test, what would we change after a positive or negative result?
Is the evidence about live birth, pregnancy tests, or a laboratory marker?
What is my estimated chance with the embryos I actually have, and how uncertain is that estimate?
What are the reasonable options if I want to pause or stop?

If the next step is another frozen transfer, use our natural-cycle frozen embryo transfer guide to prepare questions about cycle choice and timing. A protocol change should have a stated purpose; a new plan is not automatically a better plan.

Evidence behind this guide

ASRM Practice Committee, 2026: Recurrent implantation failure: a committee opinion. Professional guidance, not a new clinical trial.
ESHRE Working Group, 2023: Human Reproduction Open, hoad023. Good practice recommendations with acknowledged evidence gaps.
Durbin et al., NYU, 2026: Cumulative probability of a live birth after up to six sequential single euploid embryo transfers. Retrospective cohort; 5,811 patients.

This guide provides fertility journalism and educational information, not an individual diagnosis or treatment plan. Discuss decisions with your fertility specialist. The featured illustration is AI-generated and does not depict a real patient or a diagnostic finding.